Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | FPR2 | P25090 | 2/20 | 0.48 |
| ▸ | PYGL | P06737 | 2/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16114864 | 0.82 | POLB (0.59) | CYP2C9CYP2C19ANPEPALDH1A1KMT2A | |
| SCHEMBL5917036 | 0.82 | POLB (0.59) | CYP2C9CYP2C19ANPEPALDH1A1KMT2A | |
| SCHEMBL5917035 | 0.82 | POLB (0.59) | CYP2C9CYP2C19ANPEPALDH1A1KMT2A | |
| SCHEMBL9830901 | 0.82 | POLB (0.59) | CYP2C9CYP2C19ANPEPALDH1A1KMT2A | |
| SCHEMBL8558467 | 0.82 | FPR2 (0.44) | CYP2C9CYP2C19FPR2PYGLALDH1A1 | |
| SCHEMBL8558470 | 0.82 | FPR2 (0.44) | CYP2C9CYP2C19FPR2PYGLALDH1A1 | |
| SCHEMBL6136600 | 0.81 | POLB (0.50) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL5285749 | 0.81 | ALDH1A1 (0.49) | ALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL5966846 | 0.81 | ALDH1A1 (0.49) | ALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL6996015 | 0.81 | KMT2A (0.47) | CYP2C9CYP2C19FPR2PYGLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | CYP2C9 4299/4885CYP2C19 4445/4885FPR2 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.